Microgranulocytotoxicity.
The microcytotoxicity assay technique has been extensively refined to permit the use of granulocytes as target cells in an effort to identify neutrophil-specific antigens. Virtually every aspect of the test required revision to obtain clear, reproducible results.  The most radical modification was the adoption of double-fluorescent vital staining to detect cytotoxicity. The reactions detected with this new assay did not correlate with defined human histocompatibility systems (e.g., HLA, ABH, NA, NB, NC), nor were the target antigens detected on lymphocytes or platelets. Cytotoxicity was highly specific and was produced by the immunoglobulin fraction of alloantisera only in the presence of complement, thus implicating an antigen-antibody phenomenon rather than variable viability of the ephemeral PMN's in vitro. These specificities may have an impact on some aspects of human transplantation (especially of bone marrow) as well as playing a role in some febrile transfusion reactions. Of perhaps greater import is the suggested role of the antigens in immunoneutropenias and therefore in the response of myelosuppressed patients to adjunctive leukocyte transfusion therapy.
D000937:Antigen-Antibody Reactions; D005591:Chemical Fractionation; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes; D006098:Granulocytes / Q000276:immunology* / Q000378:metabolism; D006648:Histocompatibility; D006801:Humans; D007519:Isoantigens; D007962:Leukocytes / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology; D013194:Staining and Labeling
D000939:Epitopes; D007519:Isoantigens; D003165:Complement System Proteins